Corporate Banner
Satellite Banner
Genotyping & Gene Expression
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Randox Licenses sPLA2 CVD Risk Test from Aterovax

Published: Thursday, May 02, 2013
Last Updated: Wednesday, May 01, 2013
Bookmark and Share
Partnership to develop Aterovax’s patented biomarker sPLA2 for the assessment of cardiovascular risk.

Randox Laboratories Ltd. and Aterovax SA have announced a strategic partnership to commercialize Aterovax’s patented biomarker secreted Phospholipase A2 (sPLA2) for the assessment of cardiovascular risk. Terms of the alliance were not disclosed.

sPLA2 is a novel biomarker that independently and over and above traditional risk factors predicts adverse outcomes in patients with stable coronary artery disease and is useful in the risk stratification of patients with acute coronary syndrome.

Randox have exclusive rights to develop, manufacture and market the new test for use on automated immunoassay analyzers and will develop the sPLA2 test for its own range of analyzers and other diagnostic analyzers.

Dr. Peter FitzGerald CBE FREng, Managing Director at Randox commented “this was an exciting opportunity for Randox to expand its portfolio of CVD biomarkers and demonstrates continued investment in this field. The new SPLA2 test has been shown to add significant clinical value when combined with other biomarkers in the Randox range of tests and offers us the opportunity to provide an effective panel of tests for CVD risk assessment with strong clinical utility. The sPLA2 test will be offered to hospital laboratories through our global distribution network in 145 countries.”

Dr. Gerald Ulrich, CEO of Aterovax believes this strategic partnership will utilize the strengths of Aterovax’s many years research in CVD, especially on the development, role and clinical utility of its patented biomarker (sPLA2) in CVD risk assessment/patient stratification with Randox’s expertise in developing assays for automated immunoassay platforms and “pioneering” novel new assays in CVD biomarkers to establish a sustainable market presence for sPLA2 in the global clinical laboratory market for CVD risk assessment.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Detecting Alzheimer's with Smell Test
Odour identification test may offer low-cost alternative for predicting cognitive decline and detecting early-stage Alzheimer’s disease.
Fighting Cancer Through Protein Pathways
Researchers have found a new drug target within a protein production pathway critical to regulating growth and proliferation of cells.
Ice Bucket Challenge Instrumental in Gene Discovery
Donations from the ALS Ice Bucket Chellenge allowed for the largest-ever study of inherited ALS, which identified a new ALS gene.
Cancer Gene-Drug Combinations Ripe for Precision Medicine
The study aims to expand the number of cancer gene mutations that can be paired with a precision therapy.
New Centre Offers Ultra-Speed Protein Analysis
UW-Madison researchers to establish development centre for next-gen protein measurement technologies.
Disrupting Tumour-Promotion in Humans
Researchers have modified an existing protein to represses a specific cancer-promoting ‘message’ within cells.
Drug - Gene 'One-Two' Punch Against Cancer
Researchers identify gene-drug combinations that, together, target and kill cancer cells while not targeting healthy cells.
Drug Candidates Reduce Abnormal Protein Production
New drug candidates improve cell ability to catch miss-folded proteins that could cause deadly diseases.
Liquid Biopsies Treating Ovarian Cancer
Researchers have discovered a promising monitor and treat recurrence of ovarian cancer. Detecting cancer long before tumours reappear.
Diagnostic Thread - Weaving the Future?
Researchers have created diagnostic threads that could pave the way for next-gen implantable and wearable diagnostics.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!